Emergence of Low-level Delamanid and Bedaquiline Resistance During Extremely Drug-resistant Tuberculosis Treatment.
Silke Polsfuss;
Sabine Hofmann-Thiel;
Matthias Merker;
David Krieger;
Stefan Niemann;
Holger Rüssmann;
Nicolas Schönfeld;
Harald Hoffmann;
Katharina Kranzer 
;
(2019)
Emergence of Low-level Delamanid and Bedaquiline Resistance During Extremely Drug-resistant Tuberculosis Treatment.
CLINICAL INFECTIOUS DISEASES, 69 (7).
pp. 1229-1231.
ISSN 1058-4838
DOI: 10.1093/cid/ciz074
;
(2019)
Emergence of Low-level Delamanid and Bedaquiline Resistance During Extremely Drug-resistant Tuberculosis Treatment.
CLINICAL INFECTIOUS DISEASES, 69 (7).
pp. 1229-1231.
ISSN 1058-4838
DOI: 10.1093/cid/ciz074
Two new drugs, delamanid and bedaquiline, have recently been approved for treatment of multidrug-resistant and extensively drug-resistant (XDR) tuberculosis. Here, we report a case of clofazimine, bedaquiline, and low-level delamanid resistances acquired during treatment of a patient with XDR tuberculosis.
-
description - Manuscript_CID_accepted version.docx
-
subject - Accepted Version
-
- Available under Creative Commons: NC-ND 3.0
Downloads